Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, March 2, 2017
Wed, March 1, 2017 Market Maker Surveillance Report. DVAX, SGY, CALA, WTW, FOLD, VRML, Winning Stocks With Lowest Price Friction For Wednesday, M
March 1, 2017 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 5201 companies with "abnormal" market making, 4471 companies with positive Friction Factors and 2027 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Wednesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Dynavax Technologies Corporation (NASDAQ:DVAX), Stone Energy Corp (NYSE:SGY), Calithera Biosciences Inc. (NASDAQ:CALA), Weight Watchers International Inc. (NYSE:WTW), Amicus Therapeutics Inc. (NASDAQ:FOLD), Vermillion Inc. (NASDAQ:VRML). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Market Maker Friction Factor is shown in the chart below:
Symbol Change Percent Buy Volume Buy %% Sell Volume Sell %% Net Volume Friction DVAX $2.350 0.52% 8,061,941 40.07% 7,816,670 38.85% 245,271 1,044 SGY $19.060 2.74% 193,750 24.87% 185,976 23.87% 7,774 4 CALA $2.600 0.29% 1,099,047 37.16% 981,525 33.18% 117,522 452 WTW $3.930 0.27% 7,067,769 37.28% 6,975,720 36.80% 92,049 234 FOLD $1.110 0.17% 4,427,022 36.31% 4,324,494 35.47% 102,528 924 VRML $0.590 0.26% 107,642 42.36% 81,651 32.13% 25,991 441Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.
For example, the chart above shows DVAX with a dollar gain Wednesday of $2.35000 and a Friction Factor of 1,044 shares. That means that it only took 1,044 more shares of buying than selling to move DVAX higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.
Dynavax Technologies Corporation (NASDAQ:DVAX) - Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the United States. Its development programs focuses on vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The company s lead products include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, a C Class CpG TLR9 agonist for the treatment of cancer, which is in Phase I/II multicenter clinical trial. Its product portfolio also comprises AZD1419 for the treatment of asthma, which is in Phase II clinical trial; DV1179, a TLR7/9 inhibitor that is in Phase Ib/IIa for the treatment of autoimmune and inflammatory conditions; and DV281 and CpG-Nanoparticles, which are in preclinical studies for cancer immunotherapy. It has a research collaboration and license agreement with AstraZeneca AB to conduct a Phase IIa safety and efficacy trial of AZD1419 for the treatment of asthma; and strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California..
Stone Energy Corp (NYSE:SGY) - Stone Energy Corporation, an independent oil and natural gas company, engages in the acquisition, exploration, exploitation, development, and operation of oil and gas properties in the Gulf of Mexico. As of December 31, 2015, it had estimated proved oil and natural gas reserves of approximately 342 billion cubic feet of gas equivalent. The company was founded in 1993 and is headquartered in Lafayette, Louisiana. On December 14, 2016, Stone Energy Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas..
Calithera Biosciences Inc. (NASDAQ:CALA) - Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience s portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. In addition, it has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate Opdivo (nivolumab) in combination with CB-839 in clear cell renal cell carcinoma. The company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of CB-1158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California..
Weight Watchers International Inc. (NYSE:WTW) - Weight Watchers International, Inc. provides weight management services worldwide. The company operates in four segments: North America, United Kingdom, Continental Europe, and Other. It offers a range of products and services comprising nutritional, exercise, behavioral, and lifestyle tools and approaches. The company also engages in the meetings business, which presents weight management programs, as well as allows members to support each other by sharing their experiences with other people experiencing similar weight management challenges. In addition, it offers various digital subscription products, including Weight Watchers OnlinePlus and a weight management companion for Weight Watchers meeting members to digitally manage the day-to-day aspects of their weight management plan, as well as provides interactive and personalized resources that allow users to follow weight management plan. Further, the company provides Personal Coaching, an online subscription product that offers one-on-one telephonic, e-mail, and text support and personalized planning from a Weight Watchers-certified coach, as well as offers access to other online tools. Additionally it offers various products, including bars, snacks, cookbooks, food, and restaurant guides with SmartPoints values, Weight Watchers magazines, SmartPoints calculators, and fitness kits, as well as third-party products, such as activity-tracking monitors. The company also licenses the Weight Watchers brand and other intellectual property in frozen foods, baked goods, and other consumer products, as well as endorses selected branded consumer products; and is engaged in publishing magazines, as well issues other publications, such as cookbooks, and food and restaurant guides with SmartPoints values. It offers products through its meeting and franchisee business, as well as online. Weight Watchers International, Inc. was founded in 1961 and is headquartered in New York, New York..
Amicus Therapeutics Inc. (NASDAQ:FOLD) - Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, a small molecule, which has completed Phase III studies that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; ATB200 that is in Phase II studies to treat pompe disease; AT2221, which is in Phase II studies for the treatment of pompe disease; and AT3375 to treat Parkinson's disease. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey..
Vermillion Inc. (NASDAQ:VRML) - Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance outcomes for women. It is developing novel diagnostic tests for gynecologic disease with focus on ovarian cancer. The company s lead in vitro diagnostic test is Overa, a blood test to aid physicians in pre-surgical assessment of ovarian tumors for malignancy, using an ialgorithmic approach. It serves clinical reference laboratories, hospital laboratories, and physician offices in the United States. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas..
About BUYINS.NET
BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO
INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net
- WOPRAI
- support@woprai.com